Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00006097|
Recruitment Status : Completed
First Posted : May 4, 2004
Last Update Posted : September 22, 2010
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of CC-1088 in treating patients who have chronic lymphocytic leukemia that has not responded to previous therapy.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Drug: CC-1088||Phase 1 Phase 2|
OBJECTIVES: I. Determine the toxicity of CC-1088 in patients with refractory, progressive, B-cell chronic lymphocytic leukemia. II. Determine the response rate to this treatment in these patients.
OUTLINE: Patients receive oral CC-1088 three times a day for 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 11-20 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||CC-1088 Therapy for Chronic Lymphocytic Leukemia: A Phase I/II Trial|
|Study Start Date :||August 1999|
|Actual Primary Completion Date :||July 2005|
|Actual Study Completion Date :||July 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006097
|United States, Massachusetts|
|Boston Medical Center|
|Boston, Massachusetts, United States, 02118|
|Study Chair:||Timothy J. Ernst, MD||Boston Medical Center|